HTF Market Report released a new research document of 150 pages on industry titled as ‘Bladder and Ureter Cancer Drug Development Pipeline Review, 2017’ with detailed analysis, Competitive landscape, forecast and strategies.
About Bladder and Ureter Cancer Drug
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.
Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.
This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=908200
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies Mentioned in the Report
4SC AG, Abivax SA, Adaptimmune Therapeutics Plc, ADC Therapeutics Sarl, Altor BioScience Corp, AndroScience Corp, ANP Technologies Inc, APIM Therapeutics AS, Archivel Farma SL, Argos Therapeutics Inc, Arno Therapeutics Inc, Array BioPharma Inc, Asana BioSciences LLC, Asieris Pharmaceuticals Co Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, AVEO Pharmaceuticals Inc, Bavarian Nordic A/S, Bayer AG, Biocad, BioCancell Ltd, Biohaven Pharmaceutical Holding Company Ltd, Biomics Biotechnologies Co Ltd, Biotest AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Celgene Corp, Celldex Therapeutics Inc, Celprogen Inc, Celsion Corp, Celyad SA, Cleveland BioLabs Inc, Cold Genesys Inc, Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Eleven Biotherapeutics Inc, Eli Lilly and Co, Elsalys Biotech SAS, EpiThany Inc, Esperance Pharmaceuticals Inc, Exelixis Inc, Exicure Inc, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Gene Signal International SA, Genentech Inc, Genmab A/S, GlaxoSmithKline Plc, H3 Biomedicine Inc, Hamlet Pharma AB, Hanmi Pharmaceuticals Co Ltd, HitGen LTD, Horizon Pharma Plc, Immunocore Ltd, Immunomedics Inc, Immupharma Plc, Imugene Ltd, Incanthera Ltd, Incyte Corp, Innovation Pharmaceuticals Inc, InteRNA Technologies BV, Iovance Biotherapeutics Inc, Johnson & Johnson, Kite Pharma Inc, Laboratoires Pierre Fabre SA, LipoMedix Pharmaceutical Inc, Loxo Oncology Inc, Lycera Corp, MacroGenics Inc, Marina Biotech Inc, MaxiVAX SA, Medicenna Therapeutics Corp, MedImmune LLC, Merck & Co Inc, Merck KGaA, Mirati Therapeutics Inc, Moleculin Biotech Inc, MTG Biotherapeutics Inc, NanoCarrier Co Ltd, NantKwest Inc, Nektar Therapeutics, Novartis AG, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Optimum Therapeutics LLC, Oxford BioTherapeutics Ltd, Pfizer Inc, Pharma Mar SA, Philogen SpA, Pieris Pharmaceuticals Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Provecs Medical GmbH (Inactive), Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, Rexahn Pharmaceuticals Inc, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, Shionogi & Co Ltd, Sierra Oncology Inc, Sillajen Biotherapeutics, Sitka Biopharma Inc, Sorrento Therapeutics Inc, Spectrum Pharmaceuticals Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiwan Liposome Company Ltd, Taris Biomedical LLC, Theralase Technologies Inc, Tocagen Inc, Tolero Pharmaceuticals Inc, Transgene SA, UroGen Pharma Ltd, Vaccibody AS, Vakzine Projekt Management GmbH, Vault Pharma Inc, Vaxeal Holding SA, Vaxiion Therapeutics Inc, Viralytics Ltd, Vyriad Inc, Zymeworks Inc
Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/908200-bladder-and-ureter-cancer-drug-development-pipeline-review
It’s vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218